3D_Bioprinting_Teaser

5 More Exciting 3D Bioprinting Companies

In a previous article, we highlighted that while publicly traded investment opportunities in 3D Bioprinting are only confined at the moment to Organovo (NYSEMKT:ONVO), there are many other private companies making tracks in this space. In another article we highlighted a Swiss 3D Bioprinting startup called Insphero which is working with all top-10 pharmaceutical companies and with whom Roche and Pfizer released positive study results last year. In another article we highlighted German startup EnvisionTEC, which has been selling a 3D Bio-Printer commercially since 2001 and which is currently installed in many research universities, labs, and hospitals worldwide. In this article we will highlight 5 more 3D Bioprinting startups that are also participating in the 3D Bioprinting space. About OxSyBio London based OxSyBio was founded this year based on technology from Professor Hagan Bayley's group in the Chemistry [...]

Prudent_Vanadium_Battery

Prudent Energy’s Vanadium Flow Battery

A 2012 study conducted by Lux Research predicts that vanadium flow batteries could capture about 17 percent of the energy grid storage market by 2017, representing about $5.4 billion in potential revenue. This assumes that developers can reach a target of $750 per kilowatt hour for a fully installed system by 2017. One company that seems to be an established leader in vanadium flow batteries is Prudent Energy.       About Prudent Energy Founded in 2007, Maryland based Prudent Energy employs over 170 professionals at a number of locations in the US, Canada, and Asia. The Company taken in just over $50 million in funding so far from firms such as Draper Fisher Jurvetson, Mitsui Global Investment, Northern Light Venture Capital, and Sequoia Capital. The VRB-ESS Prudent Energy designs, manufactures and installs the patented Vanadium Redox Battery Energy Storage System (VRB-ESS) an [...]

myRisk_Teaser

myRisk: Test Yourself for 8 Hereditary Cancers

In a recent article, we discussed a hereditary breast cancer test for women called the BRACAnalysis. Statistically, it seems that the majority of women would not benefit from taking this test. The BRACAnalysis genetic test is the leading revenue stream for the company that sells it, Myriad Genetics (NASDAQ:MYGN), but has been sharply decreasing over the past year. In Q3 of this year, the BRACAnalysis only represented 44% of total revenues at $73 million. In Q3 of last year, Myriad took in just over double of that amount in BRACAnalysis revenues at $149 million or 74% of total revenues. In just a year, the revenues for BRACAnalysis have halved. The reason for this seems to be their new "myRisk" testing product which is cannibalizing BRACAnalysis with revenues of $54 million in Q3 2014 having had zero revenues in Q3 2013. myRisk Hereditary Cancer Test myRisk is a 25-gene genetic test that identifies an elevated [...]

SES_Teaser

Store Electronic Systems: An E-Ink Pure Play

In a previous article we discussed electronic ink or E-ink and how its usage will decline as the demand for e-readers declines. On the other hand, applications such as “electronic shelf labels (ESLs)” for use in retail “bricks-and-mortar” storefronts are expected to more than offset this decline. ABI Research issued a report recently titled “Next Gen Retail: Electronic Shelf Labels” in which they forecasted that revenues will increase almost six fold in the next 5 years to almost US$2 billion by 2019. In that same report, two companies were mentioned as major players that are dominating traditional ESL markets; Pricer and Store Electronics Systems (SES).       About Store Electronic Systems (SES) French- company Store Electonics Systems (EPA:SESL) or SES designs and markets electronic shelf labeling systems for food and non-food retail industries. The Company currently trades on the [...]

Manhattan_Scientific_Teaser

Manhattan Scientifics and Metallicum’s Nanometals

Who is Manhattan Scientifics? Manhattan Scientifics (OTCMKTS:MHTX) is a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. They are currently focused on two opportunities: a nanostructured metals technology (Metallicum), and a nanoparticle-based technology that provides highly sensitive cancer detection (Senior Scientific). MHTX trades as an over-the-counter (OTC) company, and therefore must be subjected to a great deal of scrutiny as most OTC companies lose investors' money. The Company has a current market cap of $58 million and a deficit of $59 million. MHTX has been up over +67% year-to-date on news of their work on cancer detection. The first focus of Manhattan on nanometals comes from their entity named Metallicum which was acquired by the Company  in 2008 for consideration of $350,000. Metallicum [...]

Lastest Articles

myRisk_Teaser

myRisk: Test Yourself for 8 Hereditary Cancers

In a recent article, we discussed a hereditary breast cancer test for women called the BRACAnalysis. Statistically, it seems that the majority of women would not benefit from taking this test. The BRACAnalysis genetic test is the leading revenue stream for the company that [...]

Prudent_Vanadium_Battery

Prudent Energy’s Vanadium Flow Battery

A 2012 study conducted by Lux Research predicts that vanadium flow batteries could capture about 17 percent of the energy grid storage market by 2017, representing about $5.4 billion in potential revenue. This assumes that developers can reach a target of $750 per kilowatt [...]

Oasys_Water_Teaser

Oasys’ Award Winning Desalination Technology

In several previous articles, we looked at the top-20  engineering, procurement and construction contractors for desalination plants constructed between the years 2000 to 2011. Of that list, only one company seemed like a viable pure-play investment in desalination. While [...]

Investing_In_Fuel_Cells_Teaser

The WilderHill Fuel Cell Index Continued

In our last article on fuel cell stocks, we took a look at the constituents of the now defunct WilderHill Fuel Cell index to see if any could be viable "pure play" fuel cell investments. While fuel cells are experiencing strong growth, especially in stationary applications [...]

Correct_Chemo_Teaser

Improving Chemotherapy with CorrectChemo

About Chemotherapy Everyone is probably familiar with the term "chemotherapy" as it relates to cancer treatment and the images it evokes are not pleasant ones mainly due to all the negative side effects the treatment is known for. One misconception about "chemotherapy" is [...]